The New Anthelmintic Tribendimidine is an L-type (Levamisole and Pyrantel) Nicotinic Acetylcholine Receptor Agonist (original) (raw)
Figure 8
Levamisole-resistant mutants are resistant to tribendimidine.
Eleven mutants isolated based on their ability to resist levamisole were subjected to dose-dependent tribendimidine mortality assays. Each data point represents viability for three independent trials for each mutant, with three wells per trial (average of 180 worms per data point). Error bars represent standard error of the mean.